S. 1133Senate117th Congress (2021-2023)In Committee

Cardiovascular Advances in Research and Opportunities Legacy Act

Introduced April 15, 2021

AI-Generated Summary

Updated February 8, 2026 at 1:40 AM UTC

The Cardiovascular Advances in Research and Opportunities Legacy Act directs the National Institutes of Health, in partnership with the National Heart, Lung, and Blood Institute, to create a dedicated program for research on valvular heart disease. It provides up to $20 million annually from 2022‑2026 for grants and a workshop on mitral‑valve prolapse, and it authorizes the CDC to run education, screening, and surveillance projects aimed at reducing sudden cardiac death from these conditions. The bill affects researchers, healthcare providers, and patients with valvular heart disease.

Key Provisions

  • NIH and NHLBI must establish a research program on valvular heart disease, with $20 million authorized each fiscal year from 2022‑2026.
  • Funding can support precision‑medicine imaging, cohort development, and predictive models for sudden cardiac arrest risk in valvular disease patients.
  • Within one year, the NHLBI must convene a workshop of experts to identify research needs and develop treatment guidelines for mitral valve prolapse.
  • CDC is authorized to carry out education, awareness, screening, and surveillance projects to prevent sudden cardiac death from valvular heart disease, including public information campaigns and grant awards.
  • CDC must collect research findings, publish best‑practice guidance for clinicians, and coordinate efforts with other public‑health agencies.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
SenateIntro Referral Latest Action

Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1984; text: CR S1985)

April 15, 2021

View full timeline
SenateIntro Referral

Introduced in Senate

April 15, 2021

SenateIntro Referral

Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1984; text: CR S1985)

April 15, 2021

Floor Debate

5 members

What members said about S. 1133 on the floor

2 Republicans3 Democrats
Dianne Feinstein
Sen. Dianne FeinsteinD-CA · Apr 15, 2021

Mr. President, I rise to speak in support of the ``Canal Conveyance Capacity Restoration Act,'' which I introduced today. Representatives Jim Costa (D-CA) has introduced companion legislation in the…

Tim Kaine
Sen. Tim KaineD-VA · Apr 15, 2021

Mr. President, it is painfully clear that existing Federal policies do not provide a comprehensive approach to address the national epidemic of gun violence. In fact, in 2019, for the third…

Mitch McConnell
Sen. Mitch McConnellR-KY · Apr 15, 2021

Madam President, time and again, prominent Democrats show they are no longer content to work within the ground rules and norms of our institutions. They prefer to threaten the institutions…

Mitch McConnell
Sen. Mitch McConnellR-KY · Apr 15, 2021

Mr. President, now, on an entirely different matter, colleagues in Congress and my fellow Kentuckians were heartbroken last June when our dear friend, Carol Leavell Barr, suddenly and unexpectedly…

Mitch McConnell
Sen. Mitch McConnellR-KY · Apr 15, 2021

Mr. President, now, on an entirely different matter, colleagues in Congress and my fellow Kentuckians were heartbroken last June when our dear friend, Carol Leavell Barr, suddenly and unexpectedly…

Show 2 more
John Thune
Sen. John ThuneR-SD · Apr 15, 2021

Mr. President, I ask unanimous consent that the text of the bill be printed in the Record.

Richard J. Durbin
Sen. Richard J. DurbinD-IL · Apr 15, 2021

Mr. President, I ask unanimous consent that the text of the bill be printed in the Record.

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in SenateIssued April 15, 2021

II

117th CONGRESS

1st Session

S. 1133

IN THE SENATE OF THE UNITED STATES

April 15, 2021

Mr. McConnell (for himself and Ms. Sinema) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program to support or conduct research on valvular heart disease, and for other purposes.

1.

Short title

This Act may be cited as the Cardiovascular Advances in Research and Opportunities Legacy Act.

2.

Grants for valvular heart disease research

Subpart 2 of part C of title IV of the Public Health Service Act (42 U.S.C. 285b et seq.) is amended by inserting after section 424C the following:

424D.

Grants for valvular heart disease research

(a)

In general

The Director of the National Institutes of Health, in consultation with the Director of the Institute, shall support or conduct research regarding valvular heart disease.

(b)

Support guidelines

The distribution of funding authorized in subsection (a) may be used to pursue any of the following outcomes:

(1)

Using precision medicine and advanced technological imaging to generate data on individuals with valvular heart disease.

(2)

Identifying and developing a cohort of individuals with valvular heart disease and available data.

(3)

Corroborating data generated through clinical trials to develop a prediction model to distinguish individuals at high risk for sudden cardiac arrest or sudden cardiac death from valvular heart disease.

(4)

Other outcomes needed to acquire necessary data on valvular heart disease.

(c)

Mitral valve prolapse workshop

Not later than one year after the date of enactment of this section, the Director of the Institute shall convene a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop prescriptive guidelines for treatment of individuals with mitral valve prolapse.

(d)

Authorization of appropriations

For the purpose of carrying out this section, there is authorized to be appropriated $20,000,000 for each of fiscal years 2022 through 2026.

.

3.

Programs of centers for disease control and prevention

Part J of title III of the Public Health Service Act (42 U.S.C. 280b et seq.) is amended by inserting after section 393D the following section:

393E.

Prevention of sudden cardiac death as a result of valvular heart disease

(a)

In general

The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may carry out projects to increase education, awareness, or diagnosis of valvular heart disease and to reduce the incidence of sudden cardiac death caused by valvular heart disease. Such projects may be carried out by the Secretary directly or through awards of grants or contracts to public or nonprofit private entities. The Secretary may directly (or through such awards) provide technical assistance with respect to the planning, development, and operation of such projects.

(b)

Certain activities

Projects carried out under subsection (a) may include—

(1)

the implementation of public information and education programs for—

(A)

the prevention of sudden cardiac death from valvular heart disease;

(B)

broadening the awareness of the public concerning the risk factors for, the symptoms of, and the public health consequences of, valvular heart disease; and

(C)

increasing screening, detection, and diagnosis of valvular heart disease; and

(2)

surveillance of out-of-hospital cardiac arrests to improve patient outcomes.

(c)

Grant prioritization

The Secretary may, in awarding grants or entering into contracts pursuant to subsection (a), give priority to entities seeking to carry out projects that target populations most impacted by valvular heart disease.

(d)

Coordination of activities

The Secretary shall ensure that activities under this section are coordinated, as appropriate, with other agencies of the Public Health Service that carry out activities regarding valvular heart disease.

(e)

Best practices

The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall—

(1)

collect and analyze the findings of research conducted with respect to valvular heart disease; and

(2)

taking into account such findings, publish on the website of the Centers for Disease Control and Prevention best practices for physicians and other health care providers who provide care to individuals with valvular heart disease.

(f)

Authorization of appropriations

For the purpose of carrying out this section, there is authorized to be appropriated such sums as may be necessary for each of fiscal years 2022 through 2026.

.